Clinical perspectives of using scintigraphy with 123-1-MIBG for assessment of sympathetic nervous system of the myocardium

Cite item

Full Text


  1. Hattori N., Schwaiger M. Metaiodobenzylguanidine scintigraphy of the heart: what have we learn clinically? Eur. J. Nucl. Med. 2000; 27: 1-6.
  2. Wieland D. M., Brown L. E., Tobes M. С. Imaging the primate adrenal medulla with 1231 and 1311 metaiodobenzylguanidine. J. Nucl. Med. 1981; 22: 358-364.
  3. Bagrado T. R., Zalutsky M. R., Vaidyanathan G. Uptake mechanisms of meta-1231-iodobenzylguanidine in isolated rat heart. Nucl. Med. Biol. 1995; 4: 2212-2218.
  4. Shapiro В., Meyers D. Metaiodobenzilguanidine to map scintigraphically the ardrenergetic nervous system in man. J. Nucl. Med. 1987; 28: 1625-1636.
  5. De Marco I., Botvinick E. Scintigraphic assessment of MBG uptake in globally denervated hearts, [bid. 1992; 33: 1444- 1450.
  6. Sugihara H., Shiga K., Terada К. Effect of exercise-induced activation of sympathetic nerve activity on clearance of 1231metaiodobenzylguanidine. Ann. Nucl. Med. 1998; 12: 175- 178.
  7. Nakajo M. Iodine-131-metaiodobenzylguanidine in extravascular accumulation in the rat heart. J. Nucl. Med. 1986; 21: 84- 89.
  8. Terada K., Sugihara H., Tatsukawa H. et al. Angle of defect on 1231-MIBG myocardial SPECT. Kaku Igaku 1997; 34: 113117.
  9. Gill J. S., Hunter G. J., Gane G., Camm A. Heterogeneity of human myocardial sympathetic innervation in vivo demonstration by iodine-123 labeled metaiodobenzylguanidine scintigraphy. Am. Heart J.1993; 126: 390-398.
  10. Simmons W. W., Freeman M. R. Abnormality cardiac sympathetic function in pacing-induced heart assessment by 123-1metaiodobenzylguanidine. Circulation 1994; 89: 2843-2851.
  11. Tsuchin S., Tamaki M. Age and gender differentiation in patients with normal neuronal function evaluated by metaiodobenzylguanidine imaging. J. Nucl. Med. 1995; 36: 969-974.
  12. Kurata C., Shouda S., Mikami T. et al. Comparison of 1231metatodobenzylguanidine kinetics with heart rate variability and plasma norepinephrine level. J. Nucl. Cardiol. 1997; 4: 515-523.
  13. Tsutsui H., Ando S. Detection of myocardial in patients with coronary artery stenosis. Am. Heart J. 1995; 129: 708-715.
  14. Sakata K., Shirotani M., Yoshida H., Kurata C. Iodine-123metaiodobenzylguanidine cardiac imaging to identify vasospastic angine without significant coronary artery stenosis. J. Am. Coll. Cardiol. 1997; 30: 370-376.
  15. Hattori N., Tamaki N., Hayashi. Regional uptake of iodine123-MIBG in diabetic hearts. J. Nucl. Med. 1996; 37: 19851990.
  16. Schnell O., Kirch С. М., Stemplinger J. et al. Scintigraphic evidence for caardiac sympathetic visualisation in long-term IDDM patients with and without ECG-based neuropathy. Diabetologia 1995; 38: 1345-1352.
  17. Merlet P. Cardiac metaiodobenzylguanidine imaging in heart failure. J. Nucl.Med. 1992; 40: 471-477.
  18. Nakata T. Cardiac imaging with metaiodobenzylguanidine in patients with heart failure. Cardiology 1998; 12: 234-240.
  19. Cohen-Solal G., Logeart D. Metaiodobenzylguanidine uptake in myocard of patients with heart failure. Cardiology 1999; 4: 3-7.
  20. Gill J. S., Hunter G. J., Ward D. E., Camm A. J. Asymmetry of cardiac 123-metaiodobenzylguanidine scans in patients with ventricular tachycardia and a "clinically normal" heart. Br. Heart J. 1993; 69: 6-13.
  21. Mitrani R. D., Klein L. S., Miles W. M. et al. Regional cardiac sympathetic denervation in patients with ventricular tachycardia in the absence of coronary artery disease. J. Am. Coll. Cardiol. 1993; 22: 1344-1353.
  22. Schafers M., Wichter T, Miles W. M. et al. Cardiac 123-1MIBG uptake in idiopathic ventricular tachycardia and fibrillation. J. Nucl. Med. 1999; 40: 1-5.
  23. McGhie A. I., Corbett J. R., Akers M. S. et al. Regional cardiac adrenergic imaging function using 1-123 metaiodobenzylguanidine tomographic imaging after acute myocardial infarction. Am. J. Cardiol. 1991; 67: 236-242.
  24. Stanton M. S., Tuli M. M. Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidine. J. Am. Coll. Cardiol. 1989; 14: 1519-1526.
  25. Yukinaka M., Nomura M., Ito S., Nakaya Y. Mismatch between myocardial accumulation of 123-1-MIBG and 99m-TcMIBI and late ventricular potentials in patients with the development of ventricular arrhythmias. Am. Heart J. 1998; 136: 859-867.
  26. Suwa M., Otake Y., Moriguchi A. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Ibid. 1997; 133: 353-358.
  27. Fukuoka S., Hayashida K., Hirose Y. et al. Use of iodine-123metaiodobenzylguanidine of beta-blocker therapy in patients with dilated cardiomyopathy. Eur. J. Nucl. Med. 1997; 24: 523-529.
  28. Lotze U., Kober A., Kaepplinger S. et al. Heart rate variability in idiopathic dilated cardiomyopathy. Am. J. Cardiol. 1999; 83: 1548-1551.
  29. Murata K., Kusachi S., Murakami T. et al. Relation of iodine123 metaiodobenzylguanidine myocardial scintigraphy to endomyocardial biopsy findings in patients with dilated cardiomyopathy. Clin. Cardiol. 1997; 20: 61-66.
  30. Suzuki Y., Toyama Т., Kanda T. et al. Prognostic significance of 1231-metaiodobenzylguanidine scintigraphy in dilated cardiomyopathy. Kaku Igaku 1995; 32: 1207-1215.
  31. Wakila Т., Numata Y., Ogata Y. et al. The relationship between the improvement of cardiac function and the myocardial uptake of 1-123 metaiodobenzylguanidine in patients with dilated cardiomyopathy treated by beta-blocker. J. Cardiol. 1995; 26: 177-183.
  32. Momose M., Kobayashi H., Saito K. et al. Two cases of dilated cardiomyopathy with the relationship between the effect of beta-blocker therapy and the changes of myocardial clearance of 1231-metaiodobenzylguanidine. Kaku Igaku 1995; 32: 301- 306.
  33. Ido A., Hasebe N., Nakamura H. et al. Clinical significance of 1231-MIBG myocardial scintigraphy in patients with hypertrophic cardiomyopathy. Ibid. 1997; 34: 807-814.
  34. Narita M., Kurihara T. Myocardial sympathetic activity and characteristics in hypertrophic cardiomyopathy: comparison with hypertensive hypertrophy. J. Cardiol. 1996; 27: 133-141.
  35. Сергиенко В. Б., Сергиенко И. В., Самойленко Л. Е. и др. Оценка плотности адренорецепторов миокарда у пациентов с ГКМП. В кн.: Материалы Второго Съезда Российского о-ва ядерной медицины. Обнинск; 2000. 2.
  36. Takatsu Н., Duncker С. М., Arai M., Becker L. С. Cardiac sympathetic nerve function assessed by [13II]metaiodobenzylguanidine after ischemia and reperfusion in anesthetized dogs. J. Nucl. Cardiol. 1997; 4: 35-41.
  37. Kramer С. М., Nicol P. D., Rogers W. J. et al. Reduced sympathetic innervation underlies adjacent noninfarcted region dysfunction during left ventricular remodeling. J. Am. Coll. Cardiol. 1997; 30: 1079-1085.
  38. Hartikainen J., Mustonen J., Kuikka J. et al. Cardiac sympathetic denervation in patients with coronary artery disease without previous myocardial infarction. Am. J. Cardiol. 1997; 80: 273-277.
  39. Hartikainen J., Kuikka J., Mantysaari M. et al. Sympathetic reinnervation after acute myocardial infarction. Ibid. 1996; 77: 5-9.
  40. Shimonagata Т., lshida X., Hayashida K. et al. Scintigraphic assessment of silent myocardial ischaemia after early infarction using myocardial SPET imaging with 201T1 and 1231MIBG. Nucl. Med. Commun. 1995; 16: 893-900.
  41. Gurtner C., Schacherer C., Krause B. J. et al. Evaluation of the sympathetic nervous system in silent ischemia with 1231-metaiodobenzylguanidine. Nuklearmedizin 1996; 35: 105-111.
  42. Nakata Т., Nagao K., Tsuchihashi K. et al. Regional cardiac sympathetic nerve dysfunction and the diagnostic efficacy of metaiodobenzylguanidine tomography in stable coronary artery disease. Am. J. Cardiol. 1996; 78: 292-297.
  43. Inobe Y., Kugiyama K., Miyagi H. et al. Long-lasting abnormalities in cardiac sympathetic nervous system in patients with coronary spastic angina: quantitative analysis with iodine-123metaiodobenzylguanidine myocardial scintigraphy. Am. Heart J. 1971; 134: 112-118.
  44. Taki J., Yasuhara S., Takamatsu T. et al. Value of iodine-123 metaiodobenzylguanidine scintigraphy in patients with vasospastic angina. Eur. J. Nucl. Med. 1998; 25: 229-234.
  45. Ha J. W., Lee J. D., Jang Y. et al. 1231-MIBG myocardial scintigraphy as a noninvasive screen for the diagnosis of coronary artery spasm. J. Nucl. Cardiol. 1998; 5: 591-597.
  46. Scherrer-Crosbie M., Mardon K., Cayla J. et al. Alterations of myocardial sympathetic innervation in response to hypoxia. J. Nucl. Med. 1997; 38: 954-957.
  47. Dae M. W., O'Connell J. W., BoWinick E. H., Chin M. С. Acute and chronic effects of transient myocardial ischemia on sympathetic nerve activity, density, and norepinephrine content. Cardiovasc.Res. 1995; 30: 270-280.

Copyright (c) 2003 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies